Showing results (21-30 of 59) with videos related to
Sort By:
Pageof 6
Clinical Breast Cancer|September 3, 2005
Current and future roles of neoadjuvant chemotherapy in operable breast cancerRyungsa Kim, Akihiko Osaki, Tetsuya TogeImmunology|September 29, 2006
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunityRyungsa Kim, Manabu Emi, Kazuaki TanabeCancers|March 13, 2024
Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to TherapyRyungsa Kim, Takanori Kin, William T BeckImmunology|March 21, 2007
Potential functional role of plasmacytoid dendritic cells in cancer immunityRyungsa Kim, Manabu Emi, Kazuaki Tanabe, et al.Breast Cancer (Tokyo, Japan)|August 20, 2002
Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancerRyungsa Kim, Akihiko Osaki, Toshihiro Hirai, et al.International Journal of Oncology|February 12, 2002
Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinomaRyungsa Kim, Kazuaki Tanabe, Hideki Inoue, et al.Cancer|October 12, 2004
Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinomaRyungsa Kim, Manabu Emi, Kazuaki Tanabe, et al.Frontiers in Oncology|February 28, 2022
Current Status and Prospects of Anesthesia and Breast Cancer: Does Anesthetic Technique Affect Recurrence and Survival Rates in Breast Cancer Surgery?Ryungsa Kim, Ami Kawai, Megumi Wakisaka, et al.Oncology Reports|May 13, 2004
Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIBRyungsa Kim, Akihiko Osaki, Kazuaki Tanabe, et al.Cancer|October 27, 2004
Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapyRyungsa Kim, Manabu Emi, Kazuaki Tanabe, et al.Pageof 6